Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design
(2015) In PLoS ONE 10(1).- Abstract
Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virtual screen, based on docking experiments, was performed to generate a FXIa targeted fragment library for an NMR screen that resulted in the identification of fragments binding in the FXIa S1 binding pocket. The neutral 6-chloro-3,4-dihydro-1H-quinolin-2-one and the weakly basic quinolin-2-amine structures are novel FXIa P1 fragments. The expansion of these fragments towards the FXIa prime side binding sites was aided by solving the X-ray structures of reported FXIa inhibitors that we found... (More)
Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virtual screen, based on docking experiments, was performed to generate a FXIa targeted fragment library for an NMR screen that resulted in the identification of fragments binding in the FXIa S1 binding pocket. The neutral 6-chloro-3,4-dihydro-1H-quinolin-2-one and the weakly basic quinolin-2-amine structures are novel FXIa P1 fragments. The expansion of these fragments towards the FXIa prime side binding sites was aided by solving the X-ray structures of reported FXIa inhibitors that we found to bind in the S1-S1'-S2' FXIa binding pockets. Combining the X-ray structure information from the identified S1 binding 6-chloro-3,4-dihydro-1H-quinolin-2-one fragment and the S1-S1'-S2' binding reference compounds enabled structure guided linking and expansion work to achieve one of the most potent and selective FXIa inhibitors reported to date, compound 13, with a FXIa IC50 of 1.0 nM. The hydrophilicity and large polar surface area of the potent S1-S1'-S2' binding FXIa inhibitors compromised permeability. Initial work to expand the 6-chloro-3,4-dihydro-1H-quinolin-2-one fragment towards the prime side to yield molecules with less hydrophilicity shows promise to afford potent, selective and orally bioavailable compounds.
(Less)
- author
- publishing date
- 2015-01-28
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Amino Acid Sequence, Binding Sites, Crystallography, X-Ray, Drug Design, Drug Evaluation, Preclinical/methods, Factor XIa/antagonists & inhibitors, Humans, Ligands, Models, Molecular, Molecular Conformation, Molecular Sequence Data, Nuclear Magnetic Resonance, Biomolecular, Peptide Library, Protein Binding, Quantitative Structure-Activity Relationship, Serine Proteinase Inhibitors/chemistry
- in
- PLoS ONE
- volume
- 10
- issue
- 1
- article number
- e0113705
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- scopus:84961290331
- pmid:25629509
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0113705
- language
- English
- LU publication?
- no
- id
- 14e89b42-2f2a-4f37-8659-f336082695de
- date added to LUP
- 2020-07-17 14:05:19
- date last changed
- 2024-02-01 03:34:38
@article{14e89b42-2f2a-4f37-8659-f336082695de,
abstract = {{<p>Activated factor XI (FXIa) inhibitors are anticipated to combine anticoagulant and profibrinolytic effects with a low bleeding risk. This motivated a structure aided fragment based lead generation campaign to create novel FXIa inhibitor leads. A virtual screen, based on docking experiments, was performed to generate a FXIa targeted fragment library for an NMR screen that resulted in the identification of fragments binding in the FXIa S1 binding pocket. The neutral 6-chloro-3,4-dihydro-1H-quinolin-2-one and the weakly basic quinolin-2-amine structures are novel FXIa P1 fragments. The expansion of these fragments towards the FXIa prime side binding sites was aided by solving the X-ray structures of reported FXIa inhibitors that we found to bind in the S1-S1'-S2' FXIa binding pockets. Combining the X-ray structure information from the identified S1 binding 6-chloro-3,4-dihydro-1H-quinolin-2-one fragment and the S1-S1'-S2' binding reference compounds enabled structure guided linking and expansion work to achieve one of the most potent and selective FXIa inhibitors reported to date, compound 13, with a FXIa IC50 of 1.0 nM. The hydrophilicity and large polar surface area of the potent S1-S1'-S2' binding FXIa inhibitors compromised permeability. Initial work to expand the 6-chloro-3,4-dihydro-1H-quinolin-2-one fragment towards the prime side to yield molecules with less hydrophilicity shows promise to afford potent, selective and orally bioavailable compounds. </p>}},
author = {{Fjellström, Ola and Akkaya, Sibel and Beisel, Hans-Georg and Eriksson, Per-Olof and Erixon, Karl and Gustafsson, David and Jurva, Ulrik and Kang, Daiwu and Karis, David and Knecht, Wolfgang and Nerme, Viveca and Nilsson, Ingemar and Olsson, Thomas and Redzic, Alma and Roth, Robert and Sandmark, Jenny and Tigerström, Anna and Öster, Linda}},
issn = {{1932-6203}},
keywords = {{Amino Acid Sequence; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical/methods; Factor XIa/antagonists & inhibitors; Humans; Ligands; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Nuclear Magnetic Resonance, Biomolecular; Peptide Library; Protein Binding; Quantitative Structure-Activity Relationship; Serine Proteinase Inhibitors/chemistry}},
language = {{eng}},
month = {{01}},
number = {{1}},
publisher = {{Public Library of Science (PLoS)}},
series = {{PLoS ONE}},
title = {{Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design}},
url = {{http://dx.doi.org/10.1371/journal.pone.0113705}},
doi = {{10.1371/journal.pone.0113705}},
volume = {{10}},
year = {{2015}},
}